Pharma players that ditch their stale culture can thrive in tough world.
The future of pharma may look pretty bleak over the next few years. The patent cliff has laid to waste blockbusters while too many drugs that were to replace them have withered on the Phase III trial vine. Productivity is low and pipelines are full of high-risk molecules with small potential markets. Big Pharma is getting the screws put to it by payers and emerging markets may not be the panacea many predict, but things look great. (...) - by Eric Palmer, FiercePharma, November 20, 2012